Myeloid Reprogramming in Critical Illness: Mechanisms, Clinical Implications, and Emerging Therapies

Abstract

Myeloid reprogramming has emerged as a central mechanism in the host response to critical illness, including sepsis, trauma, and acute respiratory distress syndrome (ARDS). This review synthesizes recent mechanistic insights, epidemiological data, clinical features, and therapeutic strategies. Special emphasis is placed on the plasticity of myeloid cells, their dysfunction in critical illness, and the translational relevance for patient management. The article also discusses risk factors, diagnostic approaches, recent advances in targeting myeloid pathways, and current guideline recommendations, providing a comprehensive resource for clinicians and researchers seeking to optimize outcomes in critically ill patients.

Introduction

Critical illness triggers profound alterations in the immune system, with myeloid cells—monocytes, macrophages, neutrophils, and dendritic cells—playing pivotal roles in both protective and pathological responses. Myeloid reprogramming refers to the functional and phenotypic changes that these cells undergo in response to systemic insults. Such reprogramming may result in either hyperinflammatory responses or immunoparalysis, both of which are linked to adverse clinical outcomes. Understanding the mechanisms driving myeloid plasticity and dysfunction lays the foundation for developing targeted therapies and improving patient prognosis.

Epidemiology / Disease Burden

Critical illness, encompassing conditions such as sepsis, ARDS, and multi-organ dysfunction syndrome (MODS), remains a major global health burden. According to recent epidemiological studies, sepsis affects over 50 million individuals annually worldwide, contributing to significant morbidity and mortality. Myeloid dysfunction has been identified in up to 70% of patients with severe sepsis and is associated with increased susceptibility to secondary infections, prolonged ICU stays, and poor long-term outcomes. The recognition of myeloid reprogramming as a hallmark of immune dysregulation underscores the need for precise immune monitoring in critically ill populations.

Pathophysiology

The pathophysiology of myeloid reprogramming in critical illness is complex and multifactorial. Acute insults such as infection, trauma, or ischemia-reperfusion injury trigger the release of damage-associated molecular patterns (DAMPs) and pathogen-associated molecular patterns (PAMPs), which activate myeloid cells via toll-like receptors and other pattern recognition receptors. This leads to epigenetic and metabolic rewiring, altering cytokine production, antigen presentation, and phagocytic capacity. The spectrum of myeloid reprogramming ranges from pro-inflammatory states—characterized by excessive cytokine release and tissue damage—to immunosuppressive phenotypes marked by impaired microbial clearance and increased risk of secondary infections. Recent evidence highlights the roles of trained immunity, myeloid-derived suppressor cells (MDSCs), and the influence of the bone marrow microenvironment in shaping these responses.

Risk Factors

Several risk factors predispose critically ill patients to maladaptive myeloid reprogramming. These include advanced age, pre-existing comorbidities (such as diabetes, chronic renal or hepatic disease), genetic polymorphisms affecting immune function, and the presence of chronic inflammation or immunosuppression prior to critical illness. Therapeutic interventions, such as corticosteroids or cytotoxic agents, can further exacerbate myeloid dysfunction. Importantly, the duration and severity of the initial insult, as well as secondary nosocomial infections, modulate the extent of myeloid plasticity and the risk of persistent immunosuppression.

Clinical Features

Myeloid reprogramming manifests clinically as either persistent inflammation, immune suppression, or a combination of both. Patients with hyperinflammatory responses may present with fever, leukocytosis, organ dysfunction, and features of systemic inflammatory response syndrome (SIRS). In contrast, immunoparalysis is characterized by recurrent or opportunistic infections, delayed wound healing, and lymphopenia. Functional assays, such as ex vivo cytokine production by monocytes in response to lipopolysaccharide (LPS), and flow cytometric analysis of surface markers (e.g., HLA-DR expression on monocytes), have been employed to identify immune dysfunction in critical care settings.

Diagnosis

Accurate diagnosis of myeloid reprogramming relies on a combination of clinical assessment and laboratory biomarkers. Flow cytometry-based evaluation of HLA-DR expression on circulating monocytes serves as a robust marker of immunoparalysis and has prognostic value in sepsis and other critical illnesses. Additional assays include quantification of cytokine responses, assessment of phagocytic activity, and detection of MDSCs using lineage and functional markers. Recent advances in single-cell transcriptomics and proteomics have enabled deeper characterization of myeloid subsets and their functional states in critically ill patients, providing opportunities for personalized immune profiling.

Treatment & Management

Management of myeloid dysfunction in critical illness is multifaceted and includes both supportive care and targeted immunomodulation. Early and appropriate antimicrobial therapy, source control, hemodynamic support, and organ support remain cornerstones of care. Immunomodulatory strategies under investigation include interferon-γ to restore monocyte function, granulocyte-macrophage colony-stimulating factor (GM-CSF), and checkpoint inhibitors targeting PD-1/PD-L1 pathways. Monitoring immune function to guide therapy is increasingly advocated, with several trials supporting individualized approaches based on immune phenotyping.

Recent Advances / Emerging Therapies

Recent research has focused on reversing maladaptive myeloid reprogramming through targeted interventions. Epigenetic modifiers, metabolic reprogramming agents, and drugs modulating the inflammasome pathway are being explored in preclinical and early-phase clinical trials. The use of cell therapies, such as ex vivo "trained" monocytes/macrophages or adoptive transfer of immune cells with restored function, represents a promising frontier. Furthermore, robust biomarker-driven strategies are being developed to identify patients at highest risk of immune dysfunction and to tailor immunotherapies accordingly.

Guideline Recommendations

Current international guidelines, including those from the Surviving Sepsis Campaign and major critical care societies, emphasize the importance of immune monitoring in critically ill patients but acknowledge that routine immunomodulation remains investigational. The use of HLA-DR expression as a biomarker is recommended for research and select clinical scenarios. Early recognition and management of secondary infections, judicious use of immunosuppressive drugs, and consideration of clinical trials for immunotherapeutic interventions are advocated in high-risk patients.

Conclusion

Myeloid reprogramming is a defining feature of the immune response in critical illness, with significant implications for patient outcomes. Advances in mechanistic understanding, diagnostics, and emerging therapies offer hope for improving care through personalized immune interventions. Future research should focus on refining biomarkers, validating immunomodulatory strategies, and integrating immune phenotyping into routine clinical practice to optimize the management of critically ill patients.